Please assess the completion status of the following clinical trial:

Trial Title: Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18-65 years~* \>50 mf/ml in finger stick blood samples~* Willing to give informed consent~Exclusion Criteria:~* Prior treatment for LF within last 5 years~* Pregnant (do pregnancy test)~* Hemoglobin \< 7 g/dl~* permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* AST/ALT and creatinine \> 1.5 upper limit of normal.~* Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- standard treatment (Type: ACTIVE_COMPARATOR): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
- DEC 6 mg/kg + Alb 400 mg x 1 (Type: EXPERIMENTAL): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
- DEC + ALB + IVM (Type: EXPERIMENTAL): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)

Based on this trial design, predict the completion outcome and termination type (if applicable).